NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
Priority Review
TENORMIN (atenolol) by AstraZeneca is clinical pharmacology atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. First approved in 1989.
Drug data last refreshed 44m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENORMIN (atenolol) is a beta-1 selective adrenergic receptor blocking agent used to treat hypertension, angina pectoris, and acute myocardial infarction. It works by reducing heart rate and cardiac output, thereby lowering blood pressure and myocardial oxygen demand. Atenolol is rapidly absorbed orally and eliminated primarily via renal excretion with minimal hepatic metabolism.
$0.004BPart D
LOE ApproachingDeclining
Shrinking revenue base and generic competition signal reduced headcount and team consolidation; career growth opportunities are limited on this legacy brand.
Mechanism of Action
CLINICAL PHARMACOLOGY Atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. This preferential effect is not absolute, however, and at higher doses, atenolol inhibits beta 2…
Worked on TENORMIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.